Ayala Pharmaceuticals Inc
(ADXS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Sales | 0 | 0 | 9 | 4 | -107 |
| Cost of Goods | 0 | N/A | 9 | 4 | 105 |
| Gross Profit | N/A | N/A | N/A | N/A | -250 |
| Operating Expenses | 8,780 | 7,131 | 8,495 | 11,873 | 17,348 |
| Operating Income | -8,780 | -7,131 | -8,486 | -11,869 | -23,046 |
| Other Income | -15,790 | -143 | -86 | 301 | -4,665 |
| Pre-tax Income | -24,570 | -7,274 | -8,572 | -11,568 | -27,711 |
| Income Tax | 103 | 65 | 127 | -4,207 | 239 |
| Net Income Continuous | -24,673 | -7,339 | -8,699 | -7,361 | -18,657 |
| Net Income | $-24,673 | $-7,339 | $-8,699 | $-7,361 | $-18,657 |
| EPS Basic Total Ops | -2.97 | -1.53 | -1.82 | -1.67 | -7.40 |
| EPS Basic Continuous Ops | -2.96 | -1.53 | -1.82 | -1.67 | -4.49 |
| EPS Diluted Total Ops | -2.97 | -1.53 | -1.82 | -1.67 | -7.40 |
| EPS Diluted Continuous Ops | -2.96 | -1.53 | -1.82 | -1.67 | -4.49 |
| EPS Diluted Before Non-Recurring Items | -2.96 | -1.53 | -1.82 | -1.67 | N/A |
| EBITDA(a) | $-8,554 | $-7,087 | $-8,431 | $-11,825 | $-17,103 |